Trials / Completed
CompletedNCT02451007
Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors
Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization (QTc Duration) in Patients With Selected Solid Tumors
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- PharmaMar · Industry
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
Study to assess the potential effects of lurbinectedin (PM01183) at a therapeutic dose on the duration of the QTc interval, measured by electrocardiograms (ECGs), to characterize the PM01183 plasma concentration/QTc relationship, and to explore related ECG parameters in patients with selected solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lurbinectedin (PM01183) |
Timeline
- Start date
- 2015-08-12
- Primary completion
- 2016-08-19
- Completion
- 2016-08-19
- First posted
- 2015-05-21
- Last updated
- 2019-11-19
- Results posted
- 2019-02-18
Locations
16 sites across 2 countries: United States, Spain
Source: ClinicalTrials.gov record NCT02451007. Inclusion in this directory is not an endorsement.